Datopotamab is a drug developed by which company?

Datopotamab Deruxtecan (Dato-DXd for short) is an antibody-drug conjugate (ADC) developed by the Japanese pharmaceutical company Daiichi Sankyo (Daiichi Sankyo ). The drug uses Daiichi Sankyo's unique DXd-ADC technology, which combines a humanized anti-TROP2 IgG1 monoclonal antibody with a topoisomerase I inhibitor payload (an ixotecan derivative). This design aims to target the TROP2 protein on the surface of tumor cells to provide precise therapeutic effects.

In2020, Daiichi Sankyo and AstraZeneca (AstraZeneca) reached a cooperation agreement. The two parties will jointly develop and commercialize dedabotomab, and AstraZeneca is responsible for the promotion and sales outside Japan. This collaboration accelerates the development and launch of dedabrotomab globally.

Dedabrotuzumab has shown good efficacy in multiple clinical trials, especially in the treatment of metastatic or locally advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC). For example, in the TROPION-Breast01 study, dabrotuzumab was shown to be effective in previously treated TNBCPatients showed a median progression-free survival (PFS) of 6.9 months, significantly reducing the risk of disease progression or death.

In short, dabrotomab is an antibody-conjugated drug targeting TROP2 developed by Daiichi Sankyo, and AstraZeneca is responsible for its promotion and sales outside Japan. The drug has shown good efficacy in multiple clinical trials, especially in the treatment of metastatic or locally advanced triple-negative breast cancer and non-small cell lung cancer. At present, dabrotuzumab has been approved in Japan, the United States, Europe and other regions, and is undergoing application and clinical research in other countries and regions such as China.

Reference materials:https://www.drugs.com/